TKThomas Alex Kodiatte

Thomas Alex Kodiatte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas Alex Kodiatte has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acute on chronic liver failure in erythropoietic protoporphyria: A case report and review of literature

    by Amith Viswanath, Rohan T Thomas, Santosh Kumar E, Uday George Zachariah, Sheethal K Jose, Meera Thomas, Thomas Alex Kodiatte

    Erythropoietic protoporphyria (EPP) is a disease caused by an inborn error of heme biosynthesis. It manifests as painful photosensitivity in childhood. Liver disease occurs due to the deposition of protoporphyrin. Cholestasis due to protoporphyrin leads to a vicious cycle of worsening, which can lead to liver failure. A 29-year-old woman presented with a three-month history of intermittent low-grade fever and a one-month history of jaundice. She had a history of painful blisters over the skin in childhood that started at two years of age and progressed to multiple contractures from healed ulcers by five years of age. She also had splenomegaly on examination. Her blood tests showed pancytopenia, hyperbilirubinemia, and elevated liver enzymes. Tropical fever workup was negative. Autoimmune hepatitis was considered, as antinuclear antibodies (ANA) were positive with elevated immunoglobulin G (IgG). Skin biopsy showed features suggestive of lipoid proteinosis. However, on review with Periodic Acid-Schiff-diastase (PAS-D) staining, a close mimic, EPP was considered a possibility. Liver biopsy showed features of EPP with infiltration with refractile brown pigment showing bright-red birefringence on polarizing microscopy. Next-generation sequencing (NGS) confirmed EPP with a ferrochelatase enzyme coding gene mutation. The patient developed pneumonia during hospitalization and developed acute on chronic liver failure (ACLF) grade 3a, as defined by the European Association for the Study of the Liver (EASL), with ascites and encephalopathy. She was treated with photoprotective measures, ursodeoxycholic acid, antibiotics, and supportive care. The family was counseled regarding options for sequential hepatic and bone marrow transplants. She was managed with the best supportive care.

  • A Novel Immunohistochemistry Classifier for Ampullary Carcinoma: Highlighting the Prognostic Power of CDX2

    by Raiza Philip, M. J. Aparna, Rijo Issac, Shailaja Balakumar, Thomas Alex Kodiatte

    Background: Ampullary carcinomas (AC) pose a diagnostic challenge while delineating into their prognostically distinct subtypes, pancreaticobiliary (PB) and intestinal (INT). This study aimed to correlate AC's histomorphological (HE) subtypes with its immunohistochemical (IHC) subtypes and evaluate their prognostic outcome. Methods: This study was conducted in the Department of Pathology at a tertiary care cancer hospital. One hundred cases of ACs in pancreatoduodenectomy specimens were selected. Slides were reviewed for HE subtyping of ACs, including Intra‐Ampullary papillary‐tubular Neoplasms into HE‐PB and HE‐INT subtypes. IHCs (MUC1, MUC2, MUC5AC, CDX2 and CK20) were performed. ACs were classified into IHC‐PB or IHC‐INT types using various IHC schemata. IHC and HE subtypes were correlated using Pearson's Chi‐square test. Sensitivity, specificity, positive predictive values, and negative predictive values were calculated for the IHCs. Survival status was analyzed using the Kaplan–Meier survival analysis. Results and Conclusion: The PB subtype showed a higher pathological tumor stage than INT. Among the various schemas evaluated, the Harthimmer Integrated Liu Layered Scoring system performed best with a significant correlation between HE and IHC subtypes. INT subtypes had better prognostic outcomes than PB subtypes. We found an essential prognostic role of CDX2 in the stratification of ACs.

  • Open Access

    A retrospective analysis of the diagnostic utility of endobronchial ultrasound guided–intranodal forceps biopsy (EBUS-IFB) in the evaluation of mediastinal adenopathy

    by Richu Bob Kurien, Priya Nadesan, Balamugesh Thangakunam, Barney Isaac, Thomas Alex Kodiatte, Reka Karuppusami

    Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the preferred diagnostic modality for evaluating mediastinal lymphadenopathy. However, its diagnostic yield is significantly reduced in conditions such as sarcoidosis, tuberculosis, and lymphoma. To address this limitation, EBUS-guided intranodal forceps biopsy (EBUS-IFB) has been proposed as an adjunct technique to enhance diagnostic accuracy in these challenging cases. This study aimed to evaluate the diagnostic yield of EBUS-IFB in the assessment of mediastinal lymphadenopathy. Methods: We retrospectively reviewed patients with mediastinal lymphadenopathy who underwent EBUS-guided intranodal forceps biopsy (EBUS-IFB). Diagnostic yield was determined using a composite reference standard (CRS), which was considered positive if a definitive diagnosis was established by any of the following: rapid on-site evaluation (ROSE), EBUS-TBNA, EBUS-IFB, bronchial biopsy, or transbronchial lung biopsy. To specifically evaluate the incremental diagnostic yield of EBUS-IFB, cases with non-diagnostic ROSE results were analysed separately. Results: Of the 40 cases with undiagnosed mediastinal lymphadenopathy, CRS was obtained in 31 cases (77.5%), while the remainder were diagnosed as reactive lymphadenopathy. Sampling adequacy was achieved in 39 out of 40 cases (97.5%). The overall diagnostic yield for EBUS-TBNA, EBUS-IFB, and combined EBUS-TBNA along with IFB (combined approach) were 54.8%, 83.9% (p value:0.03), and 90.3% (p value: 0.004) respectively. The additional diagnostic yield for EBUS-IFB and the combined approach (EBUS-TBNA + IFB) were 29.0% and 35.5% respectively, as compared to EBUS-TBNA alone. The sensitivity and specificity EBUS-IFB were 84% and 100% respectively. In subgroup analysis for cases with non-diagnostic ROSE, the diagnostic yield for EBUS-TBNA, EBUS-IFB, and the combined approach (EBUS-TBNA + IFB) were 48.2%, 85.2% (p value: 0.009) and 88.9% (p value: 0.003) respectively. The additional diagnostic yield for EBUS-IFB and the combined approach (EBUS-TBNA + IFB) were 37.0% and 40.7% respectively, as compared to EBUS-TBNA alone. The sensitivity and specificity of EBUS-IFB when ROSE was non-diagnostic were 85.2% and 100% respectively. No major complications were noted. Conclusion: The addition of IFB to routine TBNA significantly improves the diagnostic yield of EBUS, particularly in cases of non-diagnostic ROSE, with no added procedural complications.

  • Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non–Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score–Matched Analysis

    by Praveen Kumar Marimuthu, Josh Thomas Georgy, Deepa Susan Joy Philip, Ajoy Oommen John, Anjana Joel, Divya Bala Thumaty, Raju Titus Chacko, Prashant Jambunathan, Zachariah Thomas, Kovilapu Harikrishna, et al.

    PURPOSE: There is a lack of literature on treating stage III non–oncogene-driven non–small cell lung cancer (NSCLC) with low-dose immunotherapy in combination with chemotherapy for patients who are not candidates for local therapy up front. MATERIALS AND METHODS: We performed an institutional retrospective analysis of patients with stage III non–oncogene-driven NSCLC deemed ineligible for up-front local therapy. The NACT + I/O group comprised those who received induction chemotherapy in combination with low-dose nivolumab, and the NACT-alone group comprised those who received chemotherapy alone. Propensity score matching was performed based on stage, histology, and respiratory comorbid status. The primary end point was objective response rate (ORR). Secondary end points were conversion rates to local therapy, progression-free survival (PFS), overall survival (OS), and Grade ≥3 adverse events. RESULTS: Eighty-two patients were equally divided into the NACT + I/O and NACT-alone groups. The most common histology was squamous cell (60%), followed by adenocarcinoma (34%) and mixed (5%). Majority (85%) had stage IIIB or IIIC disease. The ORR to induction was 73.1% (complete response 1, partial response [PR] 29, stable disease [SD] 10, progressive disease [PD] 1) in the NACT + I/O group versus 39% (PR-16, SD-13, PD-12) in the NACT-alone group ( P = .002). The NACT + I/O group had a higher proportion of patients undergoing sequential local therapy (66% v 46.3%, P = .075), a better median PFS (not reached [NR] v 11 months, P = .0014), and median OS (NR v 28 months, P = .22) compared with the NACT-alone group at a median follow-up of 13.5 months. There were no new safety signals identified. CONCLUSION: Adding low-dose immunotherapy to chemotherapy improved ORRs, conversion rates to local therapy, and PFS in patients with stage III non–oncogene-driven NSCLC, who were ineligible for up-front local therapy.

  • Single-Centre Experience With Low-Volume Plasma Exchange and Low-Dose Steroid to Treat Patients With Idiosyncratic Drug-Induced Acute Liver Failure

    by Kunwar A. Singh, Santhosh E. Kumar, Uday G. Zachariah, Dolly Daniel, Vinoi David, Kandasamy Subramani, Kishore Pichamuthu, Ebor Jacob, Thomas A. Kodiatte, Chundamannil E. Eapen, et al.